Stellar Biotechnologies, Inc. Completes $12 Million Private Placement

Represented Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) in its $12 million private placement. The proceeds will be used for product research, aquaculture and Keyhole Limpet Hemocyanin (KLH) production development, capital expenditures and working capital. Read the press release.

Stellar Biotechnologies, Inc. is the world leader in sustainable manufacture of KLH, an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets.